Angeles Investment Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History

Angeles Investment Advisors’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,629	Closed	-$1.23M	–	135
2021 Q4	$1.23M	Sell	1,629 -646	-28%	-$483K	0.06%	75
2021 Q3	$1.7M	Buy	2,275 +926	+69%	+$694K	0.1%	56
2021 Q2	$869K	Sell	1,349 -5	-0.4%	-$3.04K	0.05%	68
2021 Q1	$773K	Buy	1,354 +170	+14%	+$101K	0.06%	59
2020 Q4	$690K	Sell	1,184 -186	-14%	-$106K	0.07%	58
2020 Q3	$706K	Buy	1,370 +745	+119%	+$377K	0.09%	42
2020 Q2	$282K	Sell	625 -184	-23%	-$81.2K	0.04%	83
2020 Q1	$327K	Buy	+809	New	+$297K	0.09%	68

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Angeles Investment Advisors's BIO Position: Q1 2022 in Review

Angeles Investment Advisors sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2022, closing a stake of 1,629 shares — an estimated $1.23M sold.

Angeles Investment Advisors first reported a position in BIO in Q1 2020 and held it in 8 quarters. The position peaked at $1.7M in Q3 2021. 515 funds tracked by Wall St. Rank hold BIO as of Q1 2022.

Angeles Investment Advisors reported no remaining Bio-Rad Laboratories Class A position as of Q1 2022 after selling out during the quarter.
Angeles Investment Advisors sold 1,629 Bio-Rad Laboratories Class A shares in Q1 2022, an estimated $1.23M.
Angeles Investment Advisors first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 8 quarters.
Angeles Investment Advisors's Bio-Rad Laboratories Class A position peaked at $1.7M in Q3 2021.
515 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2022.

Based on Angeles Investment Advisors's 13F filing for Q1 2022, filed 16 May 2022.